Bracco Imaging has launched its contrast agent MultiHance (gadobenate dimeglumine) in Russia.
MultiHance has been presented in Russia at the Nevsky Radiology Forum of St. Petersburg in a scientific symposium titled "High relaxivity or high concentration?" where the main applications and the first experiences with MultiHance in Russia were discussed, Bracco said.
MultiHance has been approved in Russia for MRI of the central nervous system, MR angiography, and for liver MRI. In other European countries MultiHance has been approved for MRI of the breast.
The first sales of MultiHance took place at the end of March, and the contrast agent is now being introduced to MRI centers in Russia, Bracco added.
